Navigation Links
AMDL Inc. Introduces New Brand Name for Its DR-70 (FDP) In Vitro Diagnostic Cancer Test
Date:7/8/2009

TUSTIN, Calif., July 8 /PRNewswire-FirstCall/ -- AMDL Inc. (NYSE Alternext US: ADL), a US-based pharmaceutical company with major operations in China, announced today the launch of a new brand name for its DR-70 (FDP) in vitro diagnostic cancer test. With today's announcement, AMDL will manufacture, market, and sell DR-70 under the more consumer-friendly, trademarked brand name Onko-Sure(TM).

Coinciding with the adoption of the new Onko-Sure(TM) brand name, AMDL also announces the successful completion of its annual ISO inspection of its Tustin, CA-based manufacturing facilities and receivership of its International Regulatory Compliance Re-certification IS0 13485:2003 for the international production of its Onko-Sure(TM) IVD cancer test.

Mr. Douglas MacLellan, Chairman and CEO of AMDL stated, "Over the past six months AMDL has been executing a very aggressive commercialization strategy for DR-70, which is progressing at a faster pace than originally expected. With several key distribution and collaboration partnerships under our belt, and more in the pipeline, we feel timing is optimal to establish a uniform and more consumer-friendly brand name for DR-70. The Onko-Sure(TM) identity represents a key milestone in AMDL's strategy for building and harmonizing an international business for this invaluable asset. We want Onko-Sure(TM) to become the undisputed #1 global brand for in vitro diagnostic cancer testing."

In the Company's view, the Onko-Sure(TM) brand offers a clearer and more concise descriptor of AMDL's IVD test, communicating it as a high quality, innovative consumer cancer test. The Company is also instilling a new tag line -- "The Power of Knowing" -- which communicates to cancer patients and their physicians the test is effective in assessing the importance of knowing whether a patient's cancer is progressing during treatment or is in remission.

AMDL's Onko-Sure(TM) in vitro diagnostic test enables physicians and their patients to effectively monitor and/or detect solid tumor cancers by measuring the accumulation of specific breakdown products in the blood called Fibrin and Fibrinogen Degradation Products (FDP). The product is researched, developed and manufactured in AMDL's Tustin, California-based facilities and sold to 3rd party distributors, which then sell directly to CLIA-certified reference laboratories in the US as well as clinical reference labs, hospital labs and physician-operated labs in the international market.

The test is approved by the US Food and Drug Administration (US FDA) for the monitoring of colorectal cancer and by Health and Canada as a lung cancer detection and monitoring tool. In addition the test is approved in Australia, Taiwan and Europe, where it has obtained the CE mark approval, as a general cancer screen. Throughout FY2009 AMDL continues to expand product commercialization into international markets based on other pending regulatory approvals. AMDL also plans to file for marketing approvals in other areas of the globe.

Commercialization of Onko-Sure(TM)

In 2009 the Company initiated an aggressive international commercialization plan for the Onko-Sure(TM) cancer test and has long-term plans to grow its IVD division into a multi-million dollar operation that complements its strong China-based pharmaceuticals division.

Mr. MacLellan continued, "We have achieved multiple key milestones this year that have never before been set in our IVD division. The adoption of the new Onko-Sure(TM) brand, combined with on-going program investments such that include collaboration with Mayo Clinic and the signing of various marketing, distribution and sales partnerships, reinforces the Company's commitment to growing our Tustin operations and ultimately achieving profitability."

AMDL continues its financing efforts with the goal of raising R&D expenditures on key business divisions. For additional information on AMDL, its latest business developments and portfolio of products, visit the Company's corporate website at www.amdl.com or contact Kristine Szarkowitz at kszarkowitz@amdl.com or 1.206.310.5323.

About AMDL:

Headquartered in Tustin, CA with operations in China, AMDL Inc., along with its subsidiary Jade Pharmaceutical Inc. (JPI), is a pharmaceutical company devoted to the research, development, manufacturing, and marketing of diagnostic, pharmaceutical, nutritional supplement, and cosmetic products. The Company employs over 510 people in the U.S. and China.

Forward Looking Statements:

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to AMDL Inc., except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

    AMDL Contact:
    Kristine Szarkowitz
    Director-Investor Relations
    kszarkowitz@amdl.com
    (Tel:) 206.310.5323


'/>"/>
SOURCE AMDL Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Delta Dental of Illinois Introduces Smile Smart For Your Health
2. Highmark Blue Cross Blue Shield Introduces New Health Plan Comparison Tool for Consumers
3. Highmark Blue Shield Introduces New Health Plan Comparison Tool for Consumers
4. Sentillion Introduces Affordable Next Generation Healthcare Single Sign-On Solution Called expreSSO(TM)
5. GladRags Introduces the Moon Cup - An Environmentally-Sound and Safe Alternative to Disposable Feminine Hygiene Products!
6. Triveris Introduces Personal Health Record with Built-in Health Advisor
7. Verizon Introduces Broadband Video Call Center Link for Deaf or Hard-of-Hearing Customers in Mid-Atlantic Region
8. Mecklenburg EMS Introduces Most-Advanced Situational Training in America for Emergency Medical Personnel
9. Small Bone Innovations Introduces the Artelon(R) STT Spacer to Increase Treatment Options for Thumb Arthritis
10. Sentillion Introduces Affordable Next Generation Healthcare Single Sign-On Solution Called expreSSO(TM)
11. ThermoTx Introduces New Mobile Stimulation (TENS) Product Line for On the Go Therapy and Pain Relief
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... Atlanta, Georgia (PRWEB) , ... March 29, 2017 , ... ... Theresa Therilus, founder of Pet Protect Law that assists dog owners in ... will assist new owners in taking the natural next step to protect their new ...
(Date:3/29/2017)... , ... March 30, 2017 , ... Sports Brand EXOUS ... brace, which retails normally at $29.97; for the remaining days of March, the price ... been reduced to a special price of just $10 (regular retail price $19.97). , ...
(Date:3/29/2017)... (PRWEB) , ... March 29, 2017 , ... ... receive FASTBRACES® in Carnegie, OK, from Dr. Jamie Cameron, with or ... teeth efficiently, compared to traditional orthodontic treatment. Depending on each patient’s case, treatment ...
(Date:3/29/2017)... Baltimore, MD (PRWEB) , ... March 29, 2017 , ... ... Maryland, is proud to announce the finalization of the company’s executive management team with ... team and leading operations is Curio Wellness’ Chief Operating Officer, Ted Dumbauld , ...
(Date:3/29/2017)... ... March 29, 2017 , ... Hamlin Dental Group, multi-location dental ... offering laser dental treatments. Dental lasers are safe and effective options, and can be ... and can improve the overall quality of care. , Dr. Hamid Reza of Hamlin ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... , March 29, 2017  Glenmark Pharmaceuticals, ... for GSP 301, an investigational fixed-dose combination of ... mcg) administered twice-daily as a nasal spray being ... These results are from a recently completed Phase ... GSP 301 combination therapy versus mometasone, olopatadine or ...
(Date:3/29/2017)... , March 29, 2017 ... a report, which provides an exhaustive study of ... study, nearly 242 companies are functional in this ... competitive. With the leading companies, such as GlaxoSmithKline ... LP, focusing aggressively on various marketing strategies to ...
(Date:3/29/2017)... Mar. 29, 2017 Research and Markets has ... report to their offering. ... The global lifestyle drugs market to grow at ... The report, Global Lifestyle Drugs Market 2017-2021, has been prepared based ... report covers the market landscape and its growth prospects over the ...
Breaking Medicine Technology: